nimodipine has been researched along with Anterior Choroidal Artery Infarction in 75 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Electronic databases (Pubmed, Embase, Web of Science and Cochrane databases) were systematically searched to identify randomized controlled trials evaluating different administration route of nimodipine (intravenous and enteral) versus placebo for treatment subarachnoid hemorrhage." | 9.41 | The efficacy of different nimodipine administration route for treating subarachnoid hemorrhage: A network meta-analysis. ( Hu, Y; Lei, G; Rao, Z, 2023) |
| "Our objective was to compare the effectiveness of intravenous and enteral nimodipine in preventing poor outcome from delayed cerebral ischemia in patients with subarachnoid hemorrhage." | 9.22 | A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis. ( Boscolo, A; Cacco, N; Carere, A; Correale, C; De Cassai, A; Diana, P; Disarò, L; Geraldini, F; Munari, M; Navalesi, P; Zampirollo, S, 2022) |
| "A total of 126 Chinese patients with post-cerebral infarction MCI recruited from the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine between April 2013 and June 2014 were randomized at 1:1: 1 ratio into nimodipine alone (30 mg/time and 3 times daily), acupuncture alone (30 min/time, 6 times/week), and nimodipine + acupuncture groups." | 9.22 | Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial. ( Gan, L; Liu, T; Wang, S; Yang, H; Zhang, B; Zhang, J; Zheng, J, 2016) |
| "The prophylactic use of nimodipine in patients with aneurysmal subarachnoid hemorrhage reduces the risk of ischemic brain damage." | 9.12 | Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. ( Briegel, J; Kunz, M; Prueckner, S; Schmid-Elsaesser, R; Steiger, HJ; Zausinger, S, 2006) |
| "Nimodipine given 7-14 days after cerebral infarction for 3 months results in memory improvement." | 9.08 | Effect of nimodipine on memory after cerebral infarction. ( Cheng, S; Sim, TC; Sze, KH; Wong, E; Woo, J, 1998) |
| "A total of 213 patients with verified aneurysmal subarachnoid hemorrhage (SAH) of Grades I to III (Hunt and Hess classification) were enrolled in a double-blind placebo-controlled trial to determine the effect of intravenous nimodipine on delayed ischemic deterioration and computerized tomography (CT)-visualized infarcts after SAH and surgery." | 9.07 | Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. ( Heiskanen, O; Ohman, J; Servo, A, 1991) |
| "Oral nimodipine 60 mg four hourly is well tolerated and reduces cerebral infarction snd improves outcome after subarachnoid haemorrhage." | 9.06 | Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. ( Foy, PM; Humphrey, PR; Illingworth, R; Lang, DA; Murray, GD; Nelson, R; Pickard, JD; Richards, P; Shaw, MD; Teasdale, GM, 1989) |
| "The authors report findings from a metaanalysis of all published randomized trials of prophylactic nimodipine used in patients who have experienced subarachnoid hemorrhage (SAH)." | 8.79 | Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. ( Barker, FG; Ogilvy, CS, 1996) |
| "Nimodipine is recommended to prevent delayed cerebral ischemia in patients with spontaneous subarachnoid hemorrhage (SAH)." | 8.31 | Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage. ( Altmann, K; Beer, R; Helbok, R; Ianosi, BA; Kindl, P; Kofler, M; Lindner, A; Pfausler, B; Putnina, L; Rass, V; Schiefecker, AJ, 2023) |
| "Intravenous and intra-arterial milrinone as a rescue measure for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been adopted by several groups, but so far, evidence for the clinical benefit is unclear and effect on brain perfusion is unknown." | 8.12 | Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Andereggen, L; Berberat, J; Ensner, R; Marbacher, S; Remonda, L; Steiger, HJ, 2022) |
| "Intra-arterial nimodipine (IAN) injections are performed in refractory delayed cerebral ischemia (DCI) related to cerebral vasospasm (CVS) after spontaneous subarachnoid hemorrhage (sSAH), but the clinical benefits are inconclusive and angiographic treatment failure is observed." | 8.12 | Analysis of Angiographic Treatment Response to Intra-Arterial Nimodipine Bolus Injection in Patients with Medically Refractory Cerebral Vasospasm After Spontaneous Subarachnoid Hemorrhage. ( Ditz, C; Küchler, J; Neumann, A; Schacht, H; Schramm, P; Tronnier, VM, 2022) |
| "The role of nimodipine and milrinone in the management of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) was studied using clinical and TCD (transcranial Doppler) parameters." | 8.12 | Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia. ( Chakrabarti, D; Konar, SK; Kotwal, A; Radhakrishnan, M; Ramalingaiah, AH; Shukla, D; Srinivasaiah, B; Sundaram, M, 2022) |
| "Conclusions: Our study results revealed that nimodipine can greatly decrease cerebral infarct size and reduce histological ischemic injury in male rats subjected to cerebral ischemia/ reperfusion." | 8.12 | POTENTIAL PROTECTIVE EFFECTS OF NIMODIPINE FROM CEREBRAI ISCHEMIA REPERFUSION INJURY IN RATS. ( Al-Mudhafar, A; Fakharaldeen, Z; Hadi, N; Radhi, A, 2022) |
| "This article investigated the clinical effects of piracetam with nimodipine in the treatment of vascular dementia (VD) after cerebral infarction." | 7.96 | Therapeutic effect of piracetam with nimodipine on vascular dementia after cerebral infarction. ( Lei, Z; Wenjing, L; Zhaomin, C; Zongfang, Z, 2020) |
| "Fifty-three percent of patients developed new cerebral infarction after intraarterial nimodipine and additional PTA in selected cases." | 7.91 | Complication rate of intraarterial treatment of severe cerebral vasospasm after subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon angioplasty: Worth the risk? ( Adami, D; Berkefeld, J; Konczalla, J; Pfeilschifter, W; Platz, J; Wagner, M; Weidauer, S, 2019) |
| "The incidence of cerebral infarction and poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH) is reduced by oral nimodipine but acute effects of the drug may include a significant decrease in mean arterial blood pressure (MAP)." | 7.83 | Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage. ( Diesing, D; Sandow, N; Sarrafzadeh, A; Vajkoczy, P; Wolf, S, 2016) |
| "This study was conducted to investigate the neuroprotective effects of 20(S)-ginsenoside Rg3 on focal cerebral ischemia in rats." | 7.73 | Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats. ( Fu, F; Geng, M; Jiang, W; Jiang, Y; Liu, K; Tian, J; Wang, C; Yang, J, 2005) |
| "To use cerebrovascular hemodynamics indexes (CVDI) to evaluate the effects of nimodipine on cerebrovascular function in acute cerebral infarction (ACI), and to investigate the changes of blood pressure (BP), heart rate (HR), and electrocardiography (ECG)." | 7.70 | [The effects of nimodipine on cerebrovascular function in acute cerebral infarction]. ( Bai, Y; Long, J; Wang, G, 1998) |
| "Focal cerebral infarction and edema were measured in rats (Wistar, Fisher 344, and spontaneously hypertensive strains) pretreated with nimodipine (2 micrograms/kg/min i." | 7.68 | Continuous nimodipine treatment attenuates cortical infarction in rats subjected to 24 hours of focal cerebral ischemia. ( Brint, S; Jacewicz, M; Pulsinelli, WA; Tanabe, J, 1990) |
| "Nimodipine is a 1,4-dihydropyridine derivative that shows a preferential cerebrovascular activity in experimental animals." | 6.67 | Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. ( Bigorra, J; Carbonell, A; Gil, P; Guillén, F; Martínez-Lage, JM; Martínez-Vila, E; Matías-Guiu, J; Villanueva, JA, 1990) |
| "Electronic databases (Pubmed, Embase, Web of Science and Cochrane databases) were systematically searched to identify randomized controlled trials evaluating different administration route of nimodipine (intravenous and enteral) versus placebo for treatment subarachnoid hemorrhage." | 5.41 | The efficacy of different nimodipine administration route for treating subarachnoid hemorrhage: A network meta-analysis. ( Hu, Y; Lei, G; Rao, Z, 2023) |
| "Rat focal cerebral ischemia was induced by reversible middle cerebral artery occlusion (MCAO) without craniectomy." | 5.29 | Influences of ginsenosides Rb1 and Rg1 on reversible focal brain ischemia in rats. ( Liu, TP; Zhang, YG, 1996) |
| "Our objective was to compare the effectiveness of intravenous and enteral nimodipine in preventing poor outcome from delayed cerebral ischemia in patients with subarachnoid hemorrhage." | 5.22 | A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis. ( Boscolo, A; Cacco, N; Carere, A; Correale, C; De Cassai, A; Diana, P; Disarò, L; Geraldini, F; Munari, M; Navalesi, P; Zampirollo, S, 2022) |
| "One of the challenges in bringing new therapeutic agents (since nimodipine) in for the treatment of cerebral ischemia associated with aneurysmal subarachnoid hemorrhage (aSAH) is the incongruence in therapeutic benefit observed between phase II and subsequent phase III clinical trials." | 5.22 | Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage. ( Broderick, JP; Cassarly, CN; Huang, W; Ishfaq, MF; Lobanova, I; Macdonald, RL; Martin, RH; Qureshi, AI; Suarez, JI, 2022) |
| "A total of 126 Chinese patients with post-cerebral infarction MCI recruited from the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine between April 2013 and June 2014 were randomized at 1:1: 1 ratio into nimodipine alone (30 mg/time and 3 times daily), acupuncture alone (30 min/time, 6 times/week), and nimodipine + acupuncture groups." | 5.22 | Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial. ( Gan, L; Liu, T; Wang, S; Yang, H; Zhang, B; Zhang, J; Zheng, J, 2016) |
| "The prophylactic use of nimodipine in patients with aneurysmal subarachnoid hemorrhage reduces the risk of ischemic brain damage." | 5.12 | Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. ( Briegel, J; Kunz, M; Prueckner, S; Schmid-Elsaesser, R; Steiger, HJ; Zausinger, S, 2006) |
| " Visible cerebral infarction on computed tomography (CT) was associated with severe stroke and an early commencement (within 24 h of stroke onset) of nimodipine treatment." | 5.11 | Blood pressure, nimodipine, and outcome of ischemic stroke. ( Erilä, T; Fogelholm, R; Kaste, M; Palomäki, H; Rissanen, A, 2004) |
| "A randomized placebo controlled double-blind clinical trial of nimodipine was conducted in 31 patients of acute cerebral infarction." | 5.08 | A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke. ( Garg, RK; Nag, D; Varma, M, 1998) |
| "Nimodipine given 7-14 days after cerebral infarction for 3 months results in memory improvement." | 5.08 | Effect of nimodipine on memory after cerebral infarction. ( Cheng, S; Sim, TC; Sze, KH; Wong, E; Woo, J, 1998) |
| "A total of 213 patients with verified aneurysmal subarachnoid hemorrhage (SAH) of Grades I to III (Hunt and Hess classification) were enrolled in a double-blind placebo-controlled trial to determine the effect of intravenous nimodipine on delayed ischemic deterioration and computerized tomography (CT)-visualized infarcts after SAH and surgery." | 5.07 | Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. ( Heiskanen, O; Ohman, J; Servo, A, 1991) |
| " Nimodipine treatment had no significant effect on the MRI findings, but delayed resuscitation was associated with probable brain edema only in placebo-treated patients." | 5.07 | Magnetic resonance imaging findings associated with cardiac arrest. ( Erkinjuntti, T; Kaste, M; Raininko, R; Roine, RO; Ylikoski, A, 1993) |
| "Oral nimodipine 60 mg four hourly is well tolerated and reduces cerebral infarction snd improves outcome after subarachnoid haemorrhage." | 5.06 | Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. ( Foy, PM; Humphrey, PR; Illingworth, R; Lang, DA; Murray, GD; Nelson, R; Pickard, JD; Richards, P; Shaw, MD; Teasdale, GM, 1989) |
| "The effects of Nimodipine on the global and regional cerebral blood flow were studied in 42 patients with cerebrovascular disorders." | 5.05 | [Effect of the Ca antagonist nimodipine on global and regional cerebrovascular circulation]. ( Bockhorn, J; Brawanski, A; Gaab, MR; Haubitz, I; Rode, CP; Schakel, EH, 1985) |
| " Clinical trials in subarachnoid hemorrhage have led to approval of nimodipine for oral and intravenous use, but other drugs, such as clazosentan, hydroxymethylglutaryl CoA reductase inhibitors (statins) and magnesium, have not shown consistent clinical efficacy." | 4.88 | Intracranial drug delivery for subarachnoid hemorrhage. ( Leung, M; Macdonald, RL; Tice, T, 2012) |
| "The authors report findings from a metaanalysis of all published randomized trials of prophylactic nimodipine used in patients who have experienced subarachnoid hemorrhage (SAH)." | 4.79 | Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. ( Barker, FG; Ogilvy, CS, 1996) |
| "Nimodipine is recommended to prevent delayed cerebral ischemia in patients with spontaneous subarachnoid hemorrhage (SAH)." | 4.31 | Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage. ( Altmann, K; Beer, R; Helbok, R; Ianosi, BA; Kindl, P; Kofler, M; Lindner, A; Pfausler, B; Putnina, L; Rass, V; Schiefecker, AJ, 2023) |
| "The role of nimodipine and milrinone in the management of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) was studied using clinical and TCD (transcranial Doppler) parameters." | 4.12 | Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia. ( Chakrabarti, D; Konar, SK; Kotwal, A; Radhakrishnan, M; Ramalingaiah, AH; Shukla, D; Srinivasaiah, B; Sundaram, M, 2022) |
| "Conclusions: Our study results revealed that nimodipine can greatly decrease cerebral infarct size and reduce histological ischemic injury in male rats subjected to cerebral ischemia/ reperfusion." | 4.12 | POTENTIAL PROTECTIVE EFFECTS OF NIMODIPINE FROM CEREBRAI ISCHEMIA REPERFUSION INJURY IN RATS. ( Al-Mudhafar, A; Fakharaldeen, Z; Hadi, N; Radhi, A, 2022) |
| "Intra-arterial nimodipine (IAN) injections are performed in refractory delayed cerebral ischemia (DCI) related to cerebral vasospasm (CVS) after spontaneous subarachnoid hemorrhage (sSAH), but the clinical benefits are inconclusive and angiographic treatment failure is observed." | 4.12 | Analysis of Angiographic Treatment Response to Intra-Arterial Nimodipine Bolus Injection in Patients with Medically Refractory Cerebral Vasospasm After Spontaneous Subarachnoid Hemorrhage. ( Ditz, C; Küchler, J; Neumann, A; Schacht, H; Schramm, P; Tronnier, VM, 2022) |
| "Intravenous and intra-arterial milrinone as a rescue measure for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been adopted by several groups, but so far, evidence for the clinical benefit is unclear and effect on brain perfusion is unknown." | 4.12 | Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Andereggen, L; Berberat, J; Ensner, R; Marbacher, S; Remonda, L; Steiger, HJ, 2022) |
| "This article investigated the clinical effects of piracetam with nimodipine in the treatment of vascular dementia (VD) after cerebral infarction." | 3.96 | Therapeutic effect of piracetam with nimodipine on vascular dementia after cerebral infarction. ( Lei, Z; Wenjing, L; Zhaomin, C; Zongfang, Z, 2020) |
| "Fifty-three percent of patients developed new cerebral infarction after intraarterial nimodipine and additional PTA in selected cases." | 3.91 | Complication rate of intraarterial treatment of severe cerebral vasospasm after subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon angioplasty: Worth the risk? ( Adami, D; Berkefeld, J; Konczalla, J; Pfeilschifter, W; Platz, J; Wagner, M; Weidauer, S, 2019) |
| "The incidence of cerebral infarction and poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH) is reduced by oral nimodipine but acute effects of the drug may include a significant decrease in mean arterial blood pressure (MAP)." | 3.83 | Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage. ( Diesing, D; Sandow, N; Sarrafzadeh, A; Vajkoczy, P; Wolf, S, 2016) |
| "This study was conducted to investigate the neuroprotective effects of 20(S)-ginsenoside Rg3 on focal cerebral ischemia in rats." | 3.73 | Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats. ( Fu, F; Geng, M; Jiang, W; Jiang, Y; Liu, K; Tian, J; Wang, C; Yang, J, 2005) |
| "To use cerebrovascular hemodynamics indexes (CVDI) to evaluate the effects of nimodipine on cerebrovascular function in acute cerebral infarction (ACI), and to investigate the changes of blood pressure (BP), heart rate (HR), and electrocardiography (ECG)." | 3.70 | [The effects of nimodipine on cerebrovascular function in acute cerebral infarction]. ( Bai, Y; Long, J; Wang, G, 1998) |
| " It is well-known, that the calcium channel blocker nimodipine reduces the incidence of cerebral infarction and ischaemic dysfunction after SAH." | 3.69 | The effect of nimodipine on autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat. ( Gjerris, F; Hauerberg, J; Juhler, M; Rasmussen, G, 1995) |
| "Focal cerebral infarction and edema were measured in rats (Wistar, Fisher 344, and spontaneously hypertensive strains) pretreated with nimodipine (2 micrograms/kg/min i." | 3.68 | Continuous nimodipine treatment attenuates cortical infarction in rats subjected to 24 hours of focal cerebral ischemia. ( Brint, S; Jacewicz, M; Pulsinelli, WA; Tanabe, J, 1990) |
| " Nimodipine-type calcium antagonists favourably affect brain perfusion and bioelectric activity which is promising for application in acute cerebral infarction." | 3.68 | [The use of nimodipine in the acute period of a cerebral infarct]. ( Kaasik, AE; Kauba, TF; Miagi, MA; Rekand, TE; Tomberg, TA, 1993) |
| "Treatment with the calcium entry blocker nimodipine is recommended as effective therapy for cerebral ischemia due to cerebral vasospasm or cerebral thrombosis." | 3.68 | [Effect of calcium antagonist nimodipine and induced hypertension on cerebral vessel reactivities, cerebral blood flow, cerebral edema and infarction in cats with one hour middle-cerebral-artery occlusion]. ( Ishida, T; Sakaki, T; Sasaoka, Y; Thunoda, S; Utsumi, S, 1990) |
| "Poor outcomes in Subarachnoid Hemorrhage (SAH) are in part due to a unique form of secondary neurological injury known as Delayed Cerebral Ischemia (DCI)." | 3.01 | Cortical Spreading Depolarization and Delayed Cerebral Ischemia; Rethinking Secondary Neurological Injury in Subarachnoid Hemorrhage. ( Bischof, H; Diedrich, D; Gomez, F; Laudanski, K; Mehra, A, 2023) |
| "Aneurysmal subarachnoid hemorrhage (aSAH) is a severe subtype of stroke occurring at a relatively young age with a significant socioeconomic impact." | 2.82 | Therapeutic Approaches for Cerebrovascular Dysfunction After Aneurysmal Subarachnoid Hemorrhage: An Update and Future Perspectives. ( Grasso, G; Torregrossa, F, 2022) |
| "One hundred and sixty patients with cerebral infarction were divided randomly into two groups." | 2.71 | [Effect of Baisuifang Granule on cognitive malfunction after cerebral infarction]. ( Chen, Y; Li, J; Li, W; Shen, XH; Tang, XM; Wang, Y; Xia, X; Yuan, CX; Zhai, Y; Zheng, L, 2004) |
| "Nimodipine is a 1,4-dihydropyridine derivative that shows a preferential cerebrovascular activity in experimental animals." | 2.67 | Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. ( Bigorra, J; Carbonell, A; Gil, P; Guillén, F; Martínez-Lage, JM; Martínez-Vila, E; Matías-Guiu, J; Villanueva, JA, 1990) |
| "Nimodipine treatment was associated with a significantly better outcome (p less than 0." | 2.66 | Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. ( Benoit, BG; Disney, LB; Gentili, F; Grace, M; Holness, RO; Khan, MI; Mohr, G; Petruk, KC; Weir, BK; West, M, 1988) |
| "Susac's syndrome is an extremely rare clinical manifestation characterized by the triad of fluctuating sensorineural hearing loss, sudden visual loss and encephalopathy." | 2.41 | [Susac syndrome as a cause of sensorineural hearing loss]. ( Albaladejo Devis, I; Cubillana Herrero, JD; Jiménez Cervantes-Nicolás, JA; Minguez Merlos, N; Rodríguez González-Herrero, B; Soler Valcárcel, A, 2002) |
| "Delayed cerebral ischemia (DCI) contributes to poor outcomes after subarachnoid hemorrhage (SAH)." | 1.72 | Large practice variations in diagnosis and treatment of delayed cerebral ischemia after subarachnoid hemorrhage. ( Coert, BA; Coutinho, JM; Horn, J; Post, R; Tjerkstra, MA; van den Berg, R; Vandertop, WP; Verbaan, D, 2022) |
| "Background and Purpose- Delayed cerebral infarction (DCI) is an important cause of morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH)." | 1.56 | Impact of Stereotactic Ventriculocisternostomy on Delayed Cerebral Infarction and Outcome After Subarachnoid Hemorrhage. ( Bardutzky, J; Beck, J; Buttler, J; Coenen, VA; Csok, I; Egger, K; Grauvogel, J; Niesen, WD; Reinacher, PC; Roelz, R; Rohr, E; Sajonz, B; Schaefer, JH; Scheiwe, C; Shah, MJ; Steiert, C, 2020) |
| "The animal model of cerebral infarction induced by Middle Cerebral Artery Occlusion (MCAO) was blocked by the suture method." | 1.56 | Protective Effect of Paeoniflorin on Acute Cerebral Infarction in Rats. ( Bao, X; Chen, Z; Feng, X; Ma, X; Qiu, C; Tao, X; Wu, W; Yang, J; Zhu, Q, 2020) |
| "Delayed Cerebral Infarction (DCI) due to Cerebral Vasospasm (CVS) is an important contributor to poor outcome after aneurysmal subarachnoid haemorrhage (aSAH)." | 1.51 | A novel rescue therapy for cerebral vasospasm: Cisternal Nimodipine application via stereotactic catheter ventriculocisternostomy. ( Coenen, VA; Reinacher, PC; Roelz, R; Scheiwe, C, 2019) |
| "We prospectively recorded clinical and demographic data, acute adverse effects related to transfusion, major hospital events, radiographic cerebral infarction, PRBC age and outcomes in 119 patients with SAH who received a PRBC transfusion." | 1.37 | Packed red blood cell age does not impact adverse events or outcomes after subarachnoid haemorrhage. ( Ault, ML; Duran, IM; Liebling, SM; Naidech, AM, 2011) |
| " There were no serious adverse effects observed." | 1.35 | Feasibility and safety of intrathecal nimodipine on posthaemorrhagic cerebral vasospasm refractory to medical and endovascular therapy. ( Beseoglu, K; Hänggi, D; Steiger, HJ; Turowski, B, 2008) |
| "We report four young women with Takayasu's arteritis who developed an ischemic stroke." | 1.29 | [Cerebrovascular complications of Takayasu's disease]. ( del Brutto, OH; Lara-Montiel, J; Lara-Terán, J; Sánchez, J, 1996) |
| "Nimodipine was given at a dose of 1 mg/kg 1 hour before and 2 hours after the cold lesion." | 1.29 | Proposed toxic oxidant inhibitors fail to reduce brain edema. ( Bulkley, GB; Hedlund, BE; Judy, KD; Long, DM, 1994) |
| "Posttreatment with lubeluzole, the S-isomer of a novel 3,4-difluoro benzothiazole, potently rescued tactile/proprioceptive hindlimb placing reactions contralateral to unilateral thrombotic infarcts in the hindlimb area of the parietal sensorimotor neocortex of rats." | 1.29 | Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. ( Claes, C; Clincke, G; De Ryck, M; Duytschaever, H; Janssen, M; Keersmaekers, R; Van Reet, G, 1996) |
| "Rat focal cerebral ischemia was induced by reversible middle cerebral artery occlusion (MCAO) without craniectomy." | 1.29 | Influences of ginsenosides Rb1 and Rg1 on reversible focal brain ischemia in rats. ( Liu, TP; Zhang, YG, 1996) |
| "The nimodipine treated animals were subdivided into hypotensive (MABP lower than 85 mmHG for more than 5 minutes after arterial occlusion) and normotensive groups." | 1.28 | [Effects of nimodipine in experimental permanent focal cerebral ischemia]. ( Marinov, M; Moskopp, D; Wassmann, H, 1992) |
| "Nimodipine was given at a dose of 0." | 1.28 | The effects of dizocilpine (MK-801), phencyclidine, and nimodipine on infarct size 48 h after middle cerebral artery occlusion in the rat. ( Beck, T; Bielenberg, GW, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (8.00) | 18.7374 |
| 1990's | 31 (41.33) | 18.2507 |
| 2000's | 13 (17.33) | 29.6817 |
| 2010's | 10 (13.33) | 24.3611 |
| 2020's | 15 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roelz, R | 3 |
| Scheiwe, C | 3 |
| Grauvogel, J | 2 |
| Csok, I | 2 |
| Coenen, VA | 3 |
| Beck, J | 2 |
| Reinacher, PC | 3 |
| Qureshi, AI | 1 |
| Lobanova, I | 1 |
| Huang, W | 1 |
| Ishfaq, MF | 1 |
| Broderick, JP | 1 |
| Cassarly, CN | 1 |
| Martin, RH | 1 |
| Macdonald, RL | 2 |
| Suarez, JI | 1 |
| Tjerkstra, MA | 1 |
| Verbaan, D | 1 |
| Coert, BA | 1 |
| Post, R | 1 |
| van den Berg, R | 1 |
| Coutinho, JM | 1 |
| Horn, J | 1 |
| Vandertop, WP | 1 |
| Steiger, HJ | 4 |
| Ensner, R | 1 |
| Andereggen, L | 1 |
| Remonda, L | 1 |
| Berberat, J | 1 |
| Marbacher, S | 1 |
| Torregrossa, F | 1 |
| Grasso, G | 1 |
| Schacht, H | 1 |
| Küchler, J | 1 |
| Neumann, A | 1 |
| Schramm, P | 1 |
| Tronnier, VM | 1 |
| Ditz, C | 1 |
| Geraldini, F | 1 |
| De Cassai, A | 1 |
| Diana, P | 1 |
| Correale, C | 1 |
| Boscolo, A | 1 |
| Zampirollo, S | 1 |
| Disarò, L | 1 |
| Carere, A | 1 |
| Cacco, N | 1 |
| Navalesi, P | 1 |
| Munari, M | 1 |
| Kotwal, A | 1 |
| Ramalingaiah, AH | 1 |
| Shukla, D | 1 |
| Radhakrishnan, M | 1 |
| Konar, SK | 1 |
| Srinivasaiah, B | 1 |
| Chakrabarti, D | 1 |
| Sundaram, M | 1 |
| Fakharaldeen, Z | 1 |
| Al-Mudhafar, A | 1 |
| Radhi, A | 1 |
| Hadi, N | 1 |
| Rass, V | 1 |
| Kindl, P | 1 |
| Lindner, A | 1 |
| Kofler, M | 1 |
| Altmann, K | 1 |
| Putnina, L | 1 |
| Ianosi, BA | 1 |
| Schiefecker, AJ | 1 |
| Beer, R | 1 |
| Pfausler, B | 1 |
| Helbok, R | 1 |
| Mehra, A | 1 |
| Gomez, F | 1 |
| Bischof, H | 1 |
| Diedrich, D | 1 |
| Laudanski, K | 1 |
| Lei, G | 1 |
| Rao, Z | 1 |
| Hu, Y | 1 |
| Schaefer, JH | 1 |
| Sajonz, B | 1 |
| Steiert, C | 1 |
| Buttler, J | 1 |
| Rohr, E | 1 |
| Shah, MJ | 1 |
| Egger, K | 1 |
| Niesen, WD | 1 |
| Bardutzky, J | 1 |
| Wu, W | 1 |
| Qiu, C | 1 |
| Feng, X | 1 |
| Tao, X | 1 |
| Zhu, Q | 1 |
| Chen, Z | 1 |
| Ma, X | 1 |
| Yang, J | 2 |
| Bao, X | 1 |
| Zongfang, Z | 1 |
| Wenjing, L | 1 |
| Zhaomin, C | 1 |
| Lei, Z | 1 |
| Zhang, C | 1 |
| Zhao, S | 1 |
| Zang, Y | 1 |
| Zhao, W | 1 |
| Song, Q | 1 |
| Feng, S | 1 |
| Hu, L | 1 |
| Gu, F | 1 |
| Adami, D | 1 |
| Berkefeld, J | 1 |
| Platz, J | 1 |
| Konczalla, J | 1 |
| Pfeilschifter, W | 1 |
| Weidauer, S | 1 |
| Wagner, M | 1 |
| Debette, S | 1 |
| Wolf, C | 1 |
| Lambert, JC | 1 |
| Crivello, F | 1 |
| Soumaré, A | 1 |
| Zhu, YC | 1 |
| Schilling, S | 1 |
| Dufouil, C | 1 |
| Mazoyer, B | 1 |
| Amouyel, P | 1 |
| Tzourio, C | 1 |
| Elbaz, A | 1 |
| Xiao, W | 1 |
| Zhang, XB | 1 |
| Hu, HX | 1 |
| Wang, Z | 1 |
| Guo, XL | 1 |
| Sandow, N | 1 |
| Diesing, D | 1 |
| Sarrafzadeh, A | 1 |
| Vajkoczy, P | 1 |
| Wolf, S | 1 |
| Wang, S | 1 |
| Yang, H | 1 |
| Zhang, J | 1 |
| Zhang, B | 1 |
| Liu, T | 1 |
| Gan, L | 1 |
| Zheng, J | 1 |
| Moran, JM | 1 |
| Pedrera-Zamorano, JD | 1 |
| Hänggi, D | 1 |
| Beseoglu, K | 1 |
| Turowski, B | 1 |
| Naidech, AM | 1 |
| Liebling, SM | 1 |
| Duran, IM | 1 |
| Ault, ML | 1 |
| Leung, M | 1 |
| Tice, T | 1 |
| Cubillana Herrero, JD | 1 |
| Soler Valcárcel, A | 1 |
| Albaladejo Devis, I | 1 |
| Rodríguez González-Herrero, B | 1 |
| Minguez Merlos, N | 1 |
| Jiménez Cervantes-Nicolás, JA | 1 |
| Sobrado, M | 1 |
| López, MG | 1 |
| Carceller, F | 2 |
| García, AG | 1 |
| Roda, JM | 2 |
| Zausinger, S | 2 |
| Westermaier, T | 1 |
| Plesnila, N | 1 |
| Schmid-Elsaesser, R | 2 |
| Nanda, S | 1 |
| Agarwal, U | 1 |
| Sangwan, K | 1 |
| Fogelholm, R | 1 |
| Palomäki, H | 1 |
| Erilä, T | 1 |
| Rissanen, A | 1 |
| Kaste, M | 2 |
| Zheng, L | 1 |
| Shen, XH | 1 |
| Wang, Y | 1 |
| Li, W | 1 |
| Zhai, Y | 1 |
| Tang, XM | 1 |
| Yuan, CX | 1 |
| Chen, Y | 1 |
| Li, J | 1 |
| Xia, X | 1 |
| Tian, J | 1 |
| Fu, F | 1 |
| Geng, M | 1 |
| Jiang, Y | 1 |
| Jiang, W | 1 |
| Wang, C | 1 |
| Liu, K | 1 |
| Wang, N | 1 |
| Kunz, M | 1 |
| Prueckner, S | 1 |
| Briegel, J | 1 |
| van den Bergh, WM | 1 |
| Mees, SM | 1 |
| Rinkel, GJ | 1 |
| Díez-Tejedor, E | 1 |
| Avendaño, C | 1 |
| Hauerberg, J | 1 |
| Rasmussen, G | 1 |
| Juhler, M | 1 |
| Gjerris, F | 1 |
| Judy, KD | 1 |
| Bulkley, GB | 1 |
| Hedlund, BE | 1 |
| Long, DM | 1 |
| Tomberg, TA | 1 |
| Miagi, MA | 1 |
| Kauba, TF | 1 |
| Rekand, TE | 1 |
| Kaasik, AE | 1 |
| Weir, B | 1 |
| MacDonald, L | 1 |
| Roine, RO | 1 |
| Raininko, R | 1 |
| Erkinjuntti, T | 1 |
| Ylikoski, A | 1 |
| McCulloch, J | 1 |
| Ozyurt, E | 1 |
| Park, CK | 1 |
| Nehls, DG | 1 |
| Teasdale, GM | 2 |
| Graham, DI | 1 |
| Nader, J | 1 |
| Bogousslavsky, J | 1 |
| Snape, MF | 1 |
| Baldwin, HA | 1 |
| Cross, AJ | 1 |
| Green, AR | 1 |
| Barker, FG | 1 |
| Ogilvy, CS | 1 |
| del Brutto, OH | 1 |
| Lara-Terán, J | 1 |
| Sánchez, J | 1 |
| Lara-Montiel, J | 1 |
| Liu, XG | 1 |
| Feng, YP | 1 |
| Zhang, YG | 1 |
| Liu, TP | 1 |
| De Ryck, M | 1 |
| Keersmaekers, R | 1 |
| Duytschaever, H | 1 |
| Claes, C | 1 |
| Clincke, G | 1 |
| Janssen, M | 1 |
| Van Reet, G | 1 |
| Jonas, S | 2 |
| Tran, AQ | 1 |
| Eisenberg, E | 1 |
| Azam, M | 1 |
| Viera, D | 1 |
| Grumet, S | 1 |
| Sze, KH | 1 |
| Sim, TC | 1 |
| Wong, E | 1 |
| Cheng, S | 1 |
| Woo, J | 1 |
| Infeld, B | 1 |
| Davis, SM | 1 |
| Donnan, GA | 1 |
| Yasaka, M | 1 |
| Lichtenstein, M | 1 |
| Mitchell, PJ | 1 |
| Fitt, GJ | 1 |
| Nag, D | 1 |
| Garg, RK | 1 |
| Varma, M | 1 |
| Long, J | 1 |
| Wang, G | 1 |
| Bai, Y | 1 |
| Korenkov, AI | 1 |
| Pahnke, J | 1 |
| Frei, K | 1 |
| Warzok, R | 1 |
| Schroeder, HW | 1 |
| Frick, R | 1 |
| Muljana, L | 1 |
| Piek, J | 1 |
| Yonekawa, Y | 1 |
| Gaab, MR | 2 |
| Quartermain, D | 1 |
| Wassmann, H | 1 |
| Marinov, M | 1 |
| Moskopp, D | 1 |
| Xu, WX | 1 |
| Guo, YP | 1 |
| Bielenberg, GW | 1 |
| Beck, T | 1 |
| Ohman, J | 1 |
| Servo, A | 1 |
| Heiskanen, O | 1 |
| Sakaki, T | 2 |
| Tsunoda, S | 1 |
| Morimoto, T | 1 |
| Handa, J | 1 |
| Shiino, A | 1 |
| Kidooka, M | 1 |
| Martínez-Vila, E | 1 |
| Guillén, F | 1 |
| Villanueva, JA | 1 |
| Matías-Guiu, J | 1 |
| Bigorra, J | 1 |
| Gil, P | 1 |
| Carbonell, A | 1 |
| Martínez-Lage, JM | 1 |
| Adams, HP | 1 |
| Jacewicz, M | 1 |
| Brint, S | 1 |
| Tanabe, J | 1 |
| Pulsinelli, WA | 1 |
| Otomo, E | 1 |
| Ishida, T | 1 |
| Sasaoka, Y | 1 |
| Thunoda, S | 1 |
| Utsumi, S | 1 |
| Pickard, JD | 1 |
| Murray, GD | 1 |
| Illingworth, R | 1 |
| Shaw, MD | 1 |
| Foy, PM | 1 |
| Humphrey, PR | 1 |
| Lang, DA | 1 |
| Nelson, R | 1 |
| Richards, P | 1 |
| Hakin, AM | 1 |
| Hakim, AM | 1 |
| Evans, AC | 1 |
| Berger, L | 1 |
| Kuwabara, H | 1 |
| Worsley, K | 1 |
| Marchal, G | 1 |
| Biel, C | 1 |
| Pokrupa, R | 1 |
| Diksic, M | 1 |
| Meyer, E | 1 |
| Gilsbach, JM | 1 |
| Harders, AG | 1 |
| Petruk, KC | 1 |
| West, M | 1 |
| Mohr, G | 1 |
| Weir, BK | 1 |
| Benoit, BG | 1 |
| Gentili, F | 1 |
| Disney, LB | 1 |
| Khan, MI | 1 |
| Grace, M | 1 |
| Holness, RO | 1 |
| Rode, CP | 1 |
| Schakel, EH | 1 |
| Haubitz, I | 1 |
| Bockhorn, J | 1 |
| Brawanski, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combining Acupuncture and Acupressure for Community-dwelling Elderly With Dementia: an Assessor-blinded, Randomized Controlled Trial[NCT04305951] | 248 participants (Anticipated) | Interventional | 2021-10-05 | Recruiting | |||
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| Prevention of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Through Treatment With Intravenous Autologous Cerebrospinal Fluid - a Pilot Trial.[NCT04490161] | 20 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for nimodipine and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III | 2022 |
Therapeutic Approaches for Cerebrovascular Dysfunction After Aneurysmal Subarachnoid Hemorrhage: An Update and Future Perspectives.
Topics: Brain Injuries; Brain Ischemia; Cerebral Infarction; Humans; Nimodipine; Quality of Life; Subarachno | 2022 |
A Comparison Between Enteral and Intravenous Nimodipine in Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis.
Topics: Brain Ischemia; Cerebral Infarction; Humans; Network Meta-Analysis; Nimodipine; Randomized Controlle | 2022 |
Cortical Spreading Depolarization and Delayed Cerebral Ischemia; Rethinking Secondary Neurological Injury in Subarachnoid Hemorrhage.
Topics: Autonomic Nervous System Diseases; Brain; Brain Ischemia; Cerebral Infarction; Humans; Nimodipine; S | 2023 |
The efficacy of different nimodipine administration route for treating subarachnoid hemorrhage: A network meta-analysis.
Topics: Administration, Intravenous; Bayes Theorem; Brain Ischemia; Cerebral Infarction; Humans; Network Met | 2023 |
Intracranial drug delivery for subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug De | 2012 |
[Susac syndrome as a cause of sensorineural hearing loss].
Topics: Adult; Anti-Inflammatory Agents; Aspirin; Cerebral Infarction; Cochlea; Combined Modality Therapy; D | 2002 |
Cerebral vasospasm.
Topics: Aneurysm, Ruptured; Blood Pressure; Blood Volume; Brain Ischemia; Catheterization; Cerebral Infarcti | 1993 |
Treatment of acute cerebral infarction.
Topics: Acute Disease; Cerebral Infarction; Female; G(M1) Ganglioside; Humans; Male; N-Methylaspartate; Nimo | 1993 |
Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis.
Topics: Brain Ischemia; Calcium Channel Blockers; Cerebral Infarction; Humans; Ischemic Attack, Transient; N | 1996 |
Does effect of a neuroprotective agent on volume of experimental animal cerebral infarct predict effect of the agent on clinical outcome in human stroke?
Topics: Animals; Cerebral Infarction; Cerebrovascular Disorders; Clinical Trials as Topic; Disease Models, A | 1997 |
Low molecular weight heparin and the treatment of ischemic stroke. Animal results, the reasons for failure in human stroke trials, mechanisms of action, and the possibilities for future use in stroke.
Topics: Animals; Anticoagulants; Calcium; Calcium Channel Blockers; Cerebral Infarction; Clinical Trials as | 2001 |
[Ca antagonists in neurosurgical practice].
Topics: Animals; Anticonvulsants; Brain; Calcium Channel Blockers; Cerebral Infarction; Disease Models, Anim | 1990 |
Calcium antagonists in the management of patients with aneurysmal subarachnoid hemorrhage: a review.
Topics: Calcium Channel Blockers; Cerebral Infarction; Humans; Intracranial Aneurysm; Ischemic Attack, Trans | 1990 |
Hemodynamic and metabolic studies in stroke.
Topics: Acidosis; Brain; Brain Ischemia; Cerebral Infarction; Cerebral Revascularization; Cerebrovascular Di | 1989 |
The effect of nimodipine on the evolution of human cerebral infarction studied by PET.
Topics: Adult; Aged; Blood Flow Velocity; Brain Ischemia; Cerebral Infarction; Cerebrovascular Circulation; | 1989 |
20 trials available for nimodipine and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Magnesium sulfate in combination with nimodipine for the treatment of subarachnoid hemorrhage: a randomized controlled clinical study.
Topics: Adult; Brain Ischemia; Cerebral Infarction; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
[Acupuncture and drug for subcortical ischemic vascular disease complicated with depression: a randomized controlled trial].
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Aged; Cerebral Infarction; Depression; Female; Fluox | 2014 |
Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial.
Topics: Acupuncture Therapy; Aged; Cerebral Infarction; Cognitive Dysfunction; Female; Humans; Male; Middle | 2016 |
Blood pressure, nimodipine, and outcome of ischemic stroke.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cerebral Infarction; Double-Blind | 2004 |
[Effect of Baisuifang Granule on cognitive malfunction after cerebral infarction].
Topics: Aged; Antihypertensive Agents; Blood Viscosity; Cerebral Infarction; Cognition Disorders; Drugs, Chi | 2004 |
Effect of the principle of activating blood circulation to break stasis on GMP-140 and D2 dimer in patients with acute cerebral infarction.
Topics: Acute Disease; Aged; Aspirin; Blood Circulation; Blood Platelets; Cerebral Infarction; Female; Fibri | 2005 |
Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
Topics: Adult; Aged; Brain Ischemia; Calcium Channel Blockers; Cerebral Angiography; Cerebral Infarction; Fe | 2006 |
Magnetic resonance imaging findings associated with cardiac arrest.
Topics: Adult; Age Factors; Aged; Atrophy; Brain Edema; Cerebral Infarction; Double-Blind Method; Female; He | 1993 |
Effect of nimodipine on memory after cerebral infarction.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Calcium Channel Blockers; Cerebral Infarction; Depress | 1998 |
Nimodipine and perfusion changes after stroke.
Topics: Acute Disease; Administration, Oral; Aged; Calcium Channel Blockers; Cerebral Infarction; Cerebrovas | 1999 |
A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke.
Topics: Adult; Aged; Brain Ischemia; Calcium Channel Blockers; Cerebral Infarction; Double-Blind Method; Fem | 1998 |
[A clinical study of recovery of memories in 46 cases of cerebrovascular diseases].
Topics: Aged; Cerebral Infarction; Double-Blind Method; Female; Humans; Male; Memory; Memory Disorders; Midd | 1991 |
Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery.
Topics: Adolescent; Adult; Aged; Cause of Death; Cerebral Infarction; Double-Blind Method; Female; Humans; I | 1991 |
Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction.
Topics: Adult; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Double-Blind Method; Female; H | 1990 |
Calcium antagonists in the management of patients with aneurysmal subarachnoid hemorrhage: a review.
Topics: Calcium Channel Blockers; Cerebral Infarction; Humans; Intracranial Aneurysm; Ischemic Attack, Trans | 1990 |
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Do | 1989 |
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Do | 1989 |
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Do | 1989 |
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cerebral Infarction; Clinical Trials as Topic; Do | 1989 |
Hemodynamic and metabolic studies in stroke.
Topics: Acidosis; Brain; Brain Ischemia; Cerebral Infarction; Cerebral Revascularization; Cerebrovascular Di | 1989 |
The effect of nimodipine on the evolution of human cerebral infarction studied by PET.
Topics: Adult; Aged; Blood Flow Velocity; Brain Ischemia; Cerebral Infarction; Cerebrovascular Circulation; | 1989 |
Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Cerebral Angiography; Cerebral Inf | 1988 |
[Effect of the Ca antagonist nimodipine on global and regional cerebrovascular circulation].
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Cerebral Infarction; Cerebrovascular Circulat | 1985 |
42 other studies available for nimodipine and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Early cisternal fibrinolysis is more effective than rescue spasmolysis for the prevention of delayed infarction after subarachnoid haemorrhage.
Topics: Cerebral Infarction; Fibrinolysis; Humans; Nimodipine; Parasympatholytics; Retrospective Studies; Su | 2022 |
Large practice variations in diagnosis and treatment of delayed cerebral ischemia after subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Humans; Nimodipine; Subarachnoid Hemorrhage; Vasospasm, Intracr | 2022 |
Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Infarction; Hemodynamics; Humans; Hypertension; Milrinone; Nimodipine; Nore | 2022 |
Analysis of Angiographic Treatment Response to Intra-Arterial Nimodipine Bolus Injection in Patients with Medically Refractory Cerebral Vasospasm After Spontaneous Subarachnoid Hemorrhage.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Humans; Infarction; Nimodipine; Retrospective Studies; Su | 2022 |
Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia.
Topics: Brain Ischemia; Cerebral Infarction; Humans; Milrinone; Nimodipine; Subarachnoid Hemorrhage; Vasospa | 2022 |
POTENTIAL PROTECTIVE EFFECTS OF NIMODIPINE FROM CEREBRAI ISCHEMIA REPERFUSION INJURY IN RATS.
Topics: Animals; Antioxidants; Brain Ischemia; Cerebral Infarction; Intercellular Adhesion Molecule-1; Inter | 2022 |
Blood Pressure Changes in Association with Nimodipine Therapy in Patients with Spontaneous Subarachnoid Hemorrhage.
Topics: Blood Pressure; Brain Ischemia; Cerebral Infarction; Humans; Hypotension; Nimodipine; Norepinephrine | 2023 |
Impact of Stereotactic Ventriculocisternostomy on Delayed Cerebral Infarction and Outcome After Subarachnoid Hemorrhage.
Topics: Aged; Aneurysm, Ruptured; Cerebral Infarction; Female; Fibrinolytic Agents; Humans; Intracranial Ane | 2020 |
Protective Effect of Paeoniflorin on Acute Cerebral Infarction in Rats.
Topics: Acute Disease; Animals; Brain; Cerebral Infarction; Disease Models, Animal; Glucosides; Lipid Peroxi | 2020 |
Therapeutic effect of piracetam with nimodipine on vascular dementia after cerebral infarction.
Topics: Aged; Calcium Channel Blockers; Case-Control Studies; Cerebral Infarction; Cerebrovascular Circulati | 2020 |
Complication rate of intraarterial treatment of severe cerebral vasospasm after subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon angioplasty: Worth the risk?
Topics: Adult; Aged; Angioplasty; Aortic Dissection; Cerebral Infarction; Combined Modality Therapy; Female; | 2019 |
A novel rescue therapy for cerebral vasospasm: Cisternal Nimodipine application via stereotactic catheter ventriculocisternostomy.
Topics: Catheters; Cerebral Infarction; Female; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Nimod | 2019 |
Abdominal obesity and lower gray matter volume: a Mendelian randomization study.
Topics: Aged; Aging; Anthropometry; Body Mass Index; Brain; Cerebral Infarction; Cohort Studies; Female; Hip | 2014 |
Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
Topics: Adult; Calcium Channel Blockers; Cerebral Infarction; Female; Humans; Intracranial Aneurysm; Male; M | 2016 |
Comments on "Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial".
Topics: Acupuncture Therapy; Cerebral Infarction; Cognitive Dysfunction; Humans; Nimodipine; Safety; Treatme | 2017 |
Feasibility and safety of intrathecal nimodipine on posthaemorrhagic cerebral vasospasm refractory to medical and endovascular therapy.
Topics: Adult; Angiography, Digital Subtraction; Calcium Channel Blockers; Cerebral Angiography; Cerebral In | 2008 |
Packed red blood cell age does not impact adverse events or outcomes after subarachnoid haemorrhage.
Topics: Adult; Aged; Blood Preservation; Cerebral Infarction; Coma; Erythrocyte Aging; Erythrocyte Transfusi | 2011 |
Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia.
Topics: Animals; Apoptosis; Brain Ischemia; Calcium Channel Blockers; Cerebral Cortex; Cerebral Infarction; | 2003 |
Neuroprotection in transient focal cerebral ischemia by combination drug therapy and mild hypothermia: comparison with customary therapeutic regimen.
Topics: Adrenal Cortex Hormones; Animals; Antioxidants; Blood Flow Velocity; Calcium Channel Blockers; Cereb | 2003 |
Successful perinatal outcome following recurrent idiopathic cerebrovascular strokes in pregnancy: a case report.
Topics: Adult; Aspirin; Cerebral Infarction; Delivery, Obstetric; Diagnosis, Differential; Drug Therapy, Com | 2003 |
Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Brain Chemistry; Brain Ischemia; Calcium Chan | 2005 |
Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
Topics: Adult; Aged; Brain Ischemia; Calcium Channel Blockers; Cerebral Angiography; Cerebral Infarction; Fe | 2006 |
Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia.
Topics: Animals; Blood Pressure; Brain Edema; Calcium Channel Blockers; Carotid Artery, External; Cerebral A | 1995 |
The effect of nimodipine on autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat.
Topics: Animals; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Infarction; Homeostasis; Male; Nimodip | 1995 |
Proposed toxic oxidant inhibitors fail to reduce brain edema.
Topics: Allopurinol; Animals; Brain Edema; Brain Injuries; Calcium; Cats; Cerebral Cortex; Cerebral Infarcti | 1994 |
[The use of nimodipine in the acute period of a cerebral infarct].
Topics: Acute Disease; Adult; Aged; Brain; Cerebral Infarction; Cerebrovascular Circulation; Drug Evaluation | 1993 |
Glutamate receptor antagonists in experimental focal cerebral ischaemia.
Topics: Animals; Brain Damage, Chronic; Brain Ischemia; Cats; Caudate Nucleus; Cerebral Cortex; Cerebral Inf | 1993 |
The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischaemia in the rat.
Topics: Animals; Body Temperature; Brain Ischemia; Cerebral Infarction; Chlormethiazole; Evans Blue; Male; N | 1993 |
[Cerebrovascular complications of Takayasu's disease].
Topics: Adolescent; Adult; Blood Sedimentation; Brain; Calcium Channel Blockers; Cerebral Angiography; Cereb | 1996 |
[Protective effect of dl-3-n-butylphthalide on ischemic neurological damage and abnormal behavior in rats subjected to focal ischemia].
Topics: Animals; Behavior, Animal; Benzofurans; Cerebral Infarction; Dizocilpine Maleate; Male; Neuroprotect | 1995 |
Influences of ginsenosides Rb1 and Rg1 on reversible focal brain ischemia in rats.
Topics: Animals; Brain; Brain Ischemia; Calcium; Calcium Channel Blockers; Cerebral Infarction; Female; Gins | 1996 |
Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats.
Topics: Animals; Brain; Cerebral Cortex; Cerebral Infarction; Dizocilpine Maleate; Dose-Response Relationshi | 1996 |
[The effects of nimodipine on cerebrovascular function in acute cerebral infarction].
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Cerebral Infarction; Cerebrovascular Circu | 1998 |
Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia.
Topics: Animals; Apoptosis; Calcium Channel Blockers; Cerebral Infarction; Corpus Striatum; Female; Free Rad | 2000 |
[Effects of nimodipine in experimental permanent focal cerebral ischemia].
Topics: Animals; Basal Ganglia; Blood Pressure; Cerebral Cortex; Cerebral Infarction; Male; Neurologic Exami | 1992 |
The effects of dizocilpine (MK-801), phencyclidine, and nimodipine on infarct size 48 h after middle cerebral artery occlusion in the rat.
Topics: Animals; Blood Glucose; Blood Pressure; Carbon Dioxide; Cerebral Arteries; Cerebral Infarction; Dizo | 1991 |
[Cerebral infarct].
Topics: Brain; Cerebral Infarction; Humans; Nimodipine; Time Factors | 1991 |
The influence of the calcium antagonist nimodipine and induced hypertension on the behavior of the cerebral pial arteries, the blood-brain barrier, cerebral edema, and cerebral infarction in cats with one-hour occlusion of the middle cerebral artery.
Topics: Animals; Blood-Brain Barrier; Brain Edema; Cats; Cerebral Arteries; Cerebral Infarction; Female; Int | 1991 |
Continuous nimodipine treatment attenuates cortical infarction in rats subjected to 24 hours of focal cerebral ischemia.
Topics: Animals; Blood Pressure; Blood Volume; Brain Edema; Brain Ischemia; Cerebral Infarction; Male; Nimod | 1990 |
[Nervous disease & Ca antagonist].
Topics: Calcium Channel Blockers; Cerebral Infarction; Cerebrovascular Disorders; Epilepsy; Flunarizine; Hum | 1990 |
[Effect of calcium antagonist nimodipine and induced hypertension on cerebral vessel reactivities, cerebral blood flow, cerebral edema and infarction in cats with one hour middle-cerebral-artery occlusion].
Topics: Animals; Blood Pressure; Brain Edema; Brain Ischemia; Cats; Cerebral Arteries; Cerebral Infarction; | 1990 |
Morbidity and mortality after early aneurysm surgery--a prospective study with nimodipine prevention.
Topics: Adult; Aged; Brain Ischemia; Cerebral Arteries; Cerebral Hemorrhage; Cerebral Infarction; Combined M | 1989 |